By Sam Boughedda
Investing.com — Shares of Pasithea Therapeutics Corp (NASDAQ:KTTA) have skyrocketed Tuesday after announcing that its subsidiary Pasithea Clinics has been approved to provide esketamine nasal spray (SPRAVATO) for treatment-resistant depression in adults.
Pasithea shares shot up 220%, to around $7.08
The biotechnology firm, which focuses on treatments for psychiatric and neurological disorders, said it has started offering the treatment in its Knightsbridge, London, location — becoming only one of three clinics in the U.K. approved to provide the treatment.
Pasithea CEO Dr. Tiago Reis Marques called the approval an "important milestone" for its U.K. clinics and their patients.
Last week, Pasithea revealed that Pasithea Clinics has launched an in-home intravenous ketamine therapy for patients suffering from similar treatment-resistant mental health issues.